Early studies with the PRLR antagonist hPRL-G129R – a variant of normal human prolactin with a single amino acid substitution mutation – revealed its capacity to inhibit the prolactin-induced oncogenic signaling responsible for cancer cell proliferation [20–24]. Here, PRLR is linked to cancer.